Accelerating Innovation and Adoption for Industry Leading eClinical
SHANGHAI--(BUSINESS WIRE)--Jun. 28, 2018--
With China based customers doubling in 2017, Medidata (NASDAQ: MDSO)
announced the appointment of Jim (Hui) Xu as general manager in the
market, and plans to double the size of local talent. Recent regulatory
changes in China are promoting faster drug approvals, and large sponsors
and partners such as Fosun Pharma, BeiGene, and WuXi CDS are joining the Medidata
Cloud, the Intelligent Platform for Life Sciences for over 1,000
global biotechnology, pharmaceutical and medical device companies.
Jim Xu brings over 24 years of unique leadership experiences across
healthcare technology and IT industries, both in China and the US.
Recently he served as CEO of the China division of Caradigm, a GE
Healthcare company, where he set up local operations and spearheaded the
company’s growth strategies. He has also worked in the health solutions
divisions at Microsoft and GE Healthcare.
“We’re excited about our fast growth and momentum in China. Jim’s
experience facilitating go-to-market strategies, product
commercialization and successful sales performance will support the high
demand for our innovative solutions tailored for the region,” said Edwin
Ng, vice president, field operations, APeJ of Medidata.
The pharmaceutical market in China is forecasted to reach $167
billion by 2020, representing an annual growth rate of 9.1%. To meet
this growing global demand, local drug and device developers are rapidly
adopting the Medidata Cloud to enhance their global footprint and drive
efficient clinical trials with a proven and scalable platform.
Medidata’s unified platform is seamlessly supporting China based
companies as they address new global regulations, including ICH E6, and
execute on their strategy to expand global studies beyond the region.
"China is a key region for life sciences, becoming the second largest
pharmaceutical market in the world and growing rapidly driven by patient
needs and innovation. Jim's appointment allows us to help our China
based customers and partners leapfrog the market and accelerate research
innovation,” said Tarek Sherif, chairman and chief executive officer,
Medidata. “Only Medidata can connect global and local CROs to the right
sponsors and streamline the way global companies develop products and
bring them to market. Our unified platform, pioneering analytics and
data, and unrivaled expertise is powering the digital transformation of
life sciences globally and provides unique value in China.”
The Medidata NEXT event series is in SeoulJuly 10 and ShanghaiJuly 12. Join Medidata executives and global life science industry
leaders to discuss the future of drug development.
Medidata accelerates the digital transformation of life sciences through
its unified platform, pioneering analytics, and unrivaled expertise. The
Intelligent Platform for Life Sciences seamlessly delivers
market-leading applications powered by artificial intelligence and
real-world analytics to reduce risk, optimize revenue, and ultimately
More than 1,000 pharmaceutical companies, biotech, medical device firms,
academic medical centers and contract research organizations around the
world can now manage and optimize value across the clinical and
commercial continuum. For more information: www.mdsol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180628005326/en/
Betsy Frank, +1
Snider, +1 646-362-2997